Acesso livre
Acesso livre

Infectologia

Estudo observacional mostra que as vacinas mRNA estão associadas à efetividade de 85% contra internação por Covid-19.

19 Nov, 2021 | 12:31h

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity – JAMA

Editorial: Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination – JAMA

Comentário: COVID-19 vaccines 85% effective against hospital cases but weaken over time – TCTMD

Estudo relacionado: Study compares the decline in effectiveness for Moderna, Pfizer, and Janssen vaccines and consequences for mortality.

8 questões sobre as novas pílulas da Merck e da Pfizer contra Covid.

19 Nov, 2021 | 12:28h

8 lingering questions about the new Covid pills from Merck and Pfizer – STAT

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Diretriz ESC para o diagnóstico e tratamento de doença cardiovascular durante a pandemia de COVID-19.

17 Nov, 2021 | 13:12h

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic – European Heart Journal

Part 1—epidemiology, pathophysiology, and diagnosis

Part 2—care pathways, treatment, and follow-up

Comunicado de imprensa: European Society of Cardiology COVID-19 guidance launched – European Society of Cardiology

 

Comentários no Twitter

 

Estudo observacional mostra que o monitoramento de pacientes com Covid-19 via mensagens de texto, propiciando que eles relatassem a piora dos sintomas, foi associado a desfechos melhores.

17 Nov, 2021 | 13:10h

Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home – Annals of Internal Medicine

Comunicado de imprensa: Automated Texting System Saved Lives Weekly During First COVID Surge – Penn Medicine

Comentários:

Monitoring outpatients by text appeared to reduce mortality from COVID-19 – ACP Internist

Texting saved lives during Covid. What does that mean for health care’s future? – STAT

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Estudo de caso-controle | Distúrbios do sono estão associados a desfechos mais graves de COVID-19.

17 Nov, 2021 | 13:08h

Comunicado de imprensa: Sleep disorders linked with more severe outcomes from COVID-19, study suggests – Cleveland Clinic

Estudo original: Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System – JAMA Network Open

Comentário: Some sleep disorders may lead to worse COVID-19 outcomes – CIDRAP

 

Comentário no Twitter

 

Grandes questões sobre as doses de reforço das vacinas contra Covid-19 – “Desde o porquê até para quem, ainda precisamos de muitas respostas sobre as doses de reforço.”

17 Nov, 2021 | 13:06h

The big questions about Covid-19 booster shots – Vox

 

Comentário no Twitter

 

Atendimento dos sintomas pós-COVID: um guia para médicos da atenção primária.

17 Nov, 2021 | 13:05h

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians – The Journal of the American Board of Family Medicine

Conteúdos relacionados:

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)

Pílula da Pfizer contra COVID deve ser fabricada e vendida mais barata em 95 países pobres.

17 Nov, 2021 | 13:03h

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries – HealthDay

Ver também:

Pfizer agrees to license generic versions of its COVID-19 pill — in some countries – NPR

Pfizer and Medicines Patent Pool Reach ‘Ground-breaking’ Voluntary Licensing Deal for New COVID-19 Treatment Pill – Health Policy Watch

Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countries – The New York Times (poucos artigos gratuitos por mês)

MSF responde à licença da Pfizer e do Medicines Patent Pool para o novo tratamento da Covid-19 – “O acordo, porém, cobre somente 53% da população mundial e exclui pessoas em diversos países de média renda, deixando esse medicamento promissor fora do alcance de milhões de pessoas.”

17 Nov, 2021 | 13:01h

MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – Médecins Sans Frontières

 

Comentário no Twitter

 

Documento de consenso IDSA/ASM | Aplicações clínicas e de prevenção de infecção da genotipagem do SARS-CoV-2.

16 Nov, 2021 | 12:48h

Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: An IDSA/ASM Consensus Review Document – Clinical Infectious Diseases

Comunicado de imprensa: New review article outlines potential of SARS-CoV-2 genetic sequencing in patient care – American Society for Microbiology

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.